RecruitingNCT06522334
Interstitial Lung Disease Registry Study: Prospective and Retrospective Observational Study in Austria
Sponsor
Ludwig Boltzmann Institute for Lung Health
Enrollment
400 participants
Start Date
Feb 28, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The goal of this registry is to systematically record epidemiological and clinical data throughout the whole interstitial lung disease course - starting with the diagnosis, therapy, follow up of lung function, symptom control, adverse events, medication, survival and death. There are no additional interventions regarding this registry.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- diagnosis of interstitial lung disease
- written informed consent
Exclusion Criteria1
- to not comprehend and rightfully judge participation
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06522334
Related Trials
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535160 locations
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT0638842167 locations
Titrated Ambulatory Oxygen in Fibrotic ILD and COPD With Isolated Exertional Hypoxemia
NCT075126871 location
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT07179380109 locations
Ultrasound and Respiratory Physiological Signals in Lung Diseases
NCT060686471 location